Invitation to the EBAC-accredited Satellite Symposium "Innovating the clinical  management of LDL-c:   Exploring CETP as therapeutic target"

For more information, please visit the ESC website.

Educational objectives

The educational objectives of the symposium are to:

•    Address the need for novel effective oral LDL-c lowering therapies as part of intensive - guideline based - lipid lowering strategies
•    Review the evolving insights and accumulating evidence with CETP inhibitors in lipid management
•    Provide an overview on the development with CETP inhibitors and future clinical landscape

Agenda

15:15 – 15:20    Introduction - Co-chairs:  Kausik Ray, MD - London, United Kingdom and Giuseppe Danilo Norata, MD, PhD - Milan, Italy

15:20 – 15:30    What do we know now that could have changed the history  of CETP Inhibition?: genetics and biology - John Kastelein, MD, PhD - Amsterdam, The Netherlands

15:30 – 15:40    CETP inhibition: Lessons from two decades of clinical trials - Stephen Nicholls, MD - Melbourne, Australia

15:40 – 15:50    A novel CETP-inhibitor to target CV risk reduction: Where could it fit in future lipid management? - Erin Michos, MD - Baltimore, MD, USA

15:50 – 16:00    Discussion - All faculty

CME Accreditation

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) with 45 minutes effective education time.  Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.

Funding

This symposium is supported by an unrestricted educational grant from NewAmsterdam Pharma and Menarini.